이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Sofiva GenomicsLtd 대차 대조표 상태

재무 상태 기준 확인 6/6

Sofiva GenomicsLtd 의 총 주주 지분은 NT$625.0M 이고 총 부채는 NT$0.0, 이는 부채 대 자기자본 비율을 0% 로 가져옵니다. 총자산과 총부채는 각각 NT$764.5M 및 NT$139.4M 입니다.

주요 정보

부채 비율

NT$0

부채

이자 보상 비율	n/a
현금	NT$119.25m
주식	NT$625.01m
총 부채	NT$139.44m
총 자산	NT$764.45m

최근 재무 상태 업데이트

업데이트 없음

Recent updates

Some Investors May Be Worried About Sofiva GenomicsLtd's (GTSM:6615) Returns On Capital

Apr 14

Estimating The Fair Value Of Sofiva Genomics Co.,Ltd. (GTSM:6615)

Mar 18

Sofiva Genomics Co.,Ltd. (GTSM:6615) Investors Should Think About This Before Buying It For Its Dividend

Feb 24

Should Weakness in Sofiva Genomics Co.,Ltd.'s (GTSM:6615) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?

Jan 27

재무 상태 분석

단기부채: 6615 의 단기 자산 ( NT$271.0M )이 단기 부채( NT$90.1M ).

장기 부채: 6615 의 단기 자산( NT$271.0M )이 장기 부채( NT$49.3M ).

부채 대 자본 내역 및 분석

부채 수준: 6615 부채가 없습니다.

부채 감소: 6615 5년 전에 부채가 없었습니다.

부채 범위: 6615 은 부채가 없으므로 영업현금흐름으로 충당할 필요가 없습니다.

이자 보장: 6615 에는 부채가 없으므로 이자 지불에 대한 보장은 문제가 되지 않습니다.

Sofiva GenomicsLtd 대차 대조표 상태

재무 상태 기준 확인 6/6

주요 정보

최근 재무 상태 업데이트

Recent updates

Investor sentiment improves as stock rises 17%

Upcoming dividend of NT$0.20 per share

Dividend reduced to NT$0.20

New major risk - Share price stability

Investor sentiment improves as stock rises 16%

First quarter 2024 earnings released: EPS: NT$0.58 (vs NT$0.20 in 1Q 2023)

Sofiva Genomics Co.,Ltd. to Report Q1, 2024 Results on May 15, 2024

New minor risk - Profit margin trend

Sofiva Genomics Co.,Ltd., Annual General Meeting, May 29, 2024

Third quarter 2023 earnings released: EPS: NT$0.27 (vs NT$0.12 in 3Q 2022)

Sofiva Genomics Co.,Ltd. Announces Resignation of Su,Yining as CEO

Sofiva Genomics Co.,Ltd. Announces Resignation of Su,Yining as CEO

Second quarter 2023 earnings released: EPS: NT$0.20 (vs NT$0.28 in 2Q 2022)

Investor sentiment improves as stock rises 18%

Upcoming dividend of NT$1.00 per share at 2.5% yield

Sofiva Genomics Co.,Ltd. Declares Cash Dividend, Payable on July 31, 2023

Investor sentiment improves as stock rises 23%

Full year 2022 earnings released: EPS: NT$2.00 (vs NT$2.68 in FY 2021)

Less than half of directors are independent

Second quarter 2022 earnings: EPS misses analyst expectations

Upcoming dividend of NT$2.00 per share

Sofiva Genomics Co.,Ltd. Announces Cash Dividend, Payable on July 28, 2022

First quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Less than half of directors are independent

Third quarter 2021 earnings released: EPS NT$0.68 (vs NT$0.28 in 3Q 2020)

Second quarter 2021 earnings released: EPS NT$0.93 (vs NT$0.40 in 2Q 2020)

Upcoming dividend of NT$1.40 per share

First quarter 2021 earnings released: EPS NT$0.42 (vs NT$0.49 in 1Q 2020)

First quarter 2021 earnings released: EPS NT$0.42 (vs NT$0.49 in 1Q 2020)

Investor sentiment improved over the past week

Some Investors May Be Worried About Sofiva GenomicsLtd's (GTSM:6615) Returns On Capital

Full year 2020 earnings released: EPS NT$1.63 (vs NT$2.96 in FY 2019)

Estimating The Fair Value Of Sofiva Genomics Co.,Ltd. (GTSM:6615)

Sofiva Genomics Co.,Ltd. (GTSM:6615) Investors Should Think About This Before Buying It For Its Dividend

Should Weakness in Sofiva Genomics Co.,Ltd.'s (GTSM:6615) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?

New 90-day low: NT$50.60

Our Take On The Returns On Capital At Sofiva GenomicsLtd (GTSM:6615)

New 90-day low: NT$51.60

A Look At The Intrinsic Value Of Sofiva Genomics Co.,Ltd. (GTSM:6615)

New 90-day low: NT$54.00

Read This Before Buying Sofiva Genomics Co.,Ltd. (GTSM:6615) For Its Dividend

Third quarter 2020 earnings released: EPS NT$0.28

New 90-day low: NT$55.00

New 90-day low - NT$55.20

New 90-day low - NT$59.00

First half earnings released

재무 상태 분석

부채 대 자본 내역 및 분석

대차 대조표

건강한 기업 발견하기